| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/CEI.12201 |
| P698 | PubMed publication ID | 24028747 |
| P2093 | author name string | Yoshihiro Matsumoto | |
| Keisuke Tanaka | |||
| Masahiko Mihara | |||
| Miho Suzuki | |||
| Hiroto Yoshida | |||
| Misato Hashizume | |||
| P2860 | cites work | IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT001065 | Q83591113 |
| IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis | Q84593093 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis | Q24564656 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis | Q24800726 | ||
| CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts | Q28210471 | ||
| MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation | Q28236005 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis | Q28593488 | ||
| A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis | Q34413330 | ||
| Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo | Q34420830 | ||
| 1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis | Q36297015 | ||
| Finding a way out: lymphocyte egress from lymphoid organs | Q37008187 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Osteoimmunology and the effects of the immune system on bone | Q37626412 | ||
| Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts | Q38328790 | ||
| CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis | Q39720295 | ||
| Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption | Q39773087 | ||
| High-resolution three-dimensional micro-computed tomography detects bone loss and changes in trabecular architecture early: comparison with DEXA and bone histomorphometry in a rat model of disuse osteoporosis. | Q43830666 | ||
| Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study | Q45271842 | ||
| Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system | Q46280827 | ||
| Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. | Q50697468 | ||
| Effect of raloxifene on arthritis and bone mineral density in rats with collagen-induced arthritis. | Q51529501 | ||
| Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. | Q51746101 | ||
| Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. | Q53567358 | ||
| High-resolution micro-CT evaluation of mid- to long-term effects of estrogen deficiency on rat trabecular bone1 | Q53639300 | ||
| LPS and TNF-α induce expression of sphingosine-1-phosphate receptor-2 in human microvascular endothelial cells. | Q54329465 | ||
| Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans | Q57225024 | ||
| Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation | Q71437425 | ||
| A microtomographic system for the nondestructive evaluation of bone architecture | Q71576009 | ||
| Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration | Q73831121 | ||
| A morphometric comparison of trabecular structure of human ilium between microcomputed tomography and conventional histomorphometry | Q73909301 | ||
| Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma | Q73971509 | ||
| Characterization of anti-mouse interleukin-6 receptor antibody | Q78467480 | ||
| Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis | Q81158300 | ||
| Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy | Q82357642 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 172-180 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model | |
| P478 | volume | 175 |
| Q36302388 | Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis |
| Q26774874 | Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review |
| Q64956206 | Arsenic Trioxide in Synergy with Vitamin D Rescues the Defective VDR-PPAR-γ Functional Module of Autophagy in Rheumatoid Arthritis. |
| Q24701763 | Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection |
| Q34252489 | Cytokine-mediated bone destruction in rheumatoid arthritis |
| Q60916226 | Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma |
| Q92646597 | Mast cells enhance sterile inflammation in chronic nonbacterial osteomyelitis |
| Q36189808 | Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice |
| Q47881999 | Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair. |
| Q90187449 | Sphingosine-1-phosphate (S1P) receptors: Promising drug targets for treating bone-related diseases |
| Q38831693 | The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study |
| Q92757089 | The effect of anti-IL-6 receptor antibody for the treatment of McH-lpr/lpr-RA1 mice that spontaneously developed destructive arthritis and enthesitis |
| Q46671185 | Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. |
Search more.